Neurogene Inc. (NGNE) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US64135M1053
Neurogene Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -103.33 m USD |
| EBIT | -101.89 m USD |
| Net income | -90.35 m USD |
| Diluted EPS – continuing operations | -4.24 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
More stocks
- Xiamen Sunrise Wheel Group Co Ltd (002593.SZ)
- AUPU Home Style Corp Ltd (603551.SS)
- ADAMAS TRUST, INC. (ADAM)
- Hefei Lifeon Pharmaceutical Co Ltd (003020.SZ)
- DiaMedica Therapeutics Inc. (DMAC)
- ETHAN ALLEN INTERIORS INC (ETD)
- Grupo Empresarial San Jose SA (GSJ.MC)
- GREENLIGHT CAPITAL RE, LTD. (GLRE)
- Beijing Scitop Bio Tech Co Ltd (300858.SZ)
- SUNSEA Telecommunications Co Ltd (002313.SZ)
- Xinjiang Sailing Information Technology Co Ltd (300588.SZ)
- Healthcare Co Ltd (603313.SS)
Not investment advice. All data without warranty, price as of 09.11.2026. Details in the risk notice.